Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Major bleeding during combined treatment with indomethacin and low doses of acenocoumarol in a homozygous patient for 2C9*3 variant of cytochrome p-450 CYP2C9.

Thrombosis and haemostasis - 1 Jul 2003

Zarza José

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acenocoumarol
Share to Benzodiazepines
Share to Drug Interactions
Share to Gastric Mucosa

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Hemorrhage

Share to Inactivation, Metabolic

Share to Indomethacin

Share to Ischemic Attack, Transient

Source

Identifiers

PMID: 12876643

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Major bleeding during combined treatment with indomethacin and low doses of acenocoumarol in a homozygous patient for 2C9*3 variant of cytochrome p-450 CYP2C9.PMID 12876643Read ↗

Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers.Semantic proximity Read ↗

The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.Semantic proximity Read ↗

Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding.Semantic proximity Read ↗

Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.Semantic proximity Read ↗

Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?Semantic proximity Read ↗

Cytochrome P450 2C9 polymorphism and acenocoumarol therapy.Semantic proximity Read ↗

Effect of polymorphisms in the cytochrome P450 CYP2C9 gene on warfarin anticoagulation.Semantic proximity Read ↗

The relationship between CYP2C9 gene polymorphisms and upper gastrointestinal bleeding in patients who used warfarin.Semantic proximity Read ↗

The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol.Semantic proximity Read ↗

Warfarin therapy in a patient homozygous for the CYP2C9 3 allele.Semantic proximity Read ↗

The influence of polymorphisms of VKORC1 and CYP2C9 on major gastrointestinal bleeding risk in anticoagulated patients.Semantic proximity Read ↗

Association of CYP2C9 gene polymorphism with bleeding as a complication of warfarin therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.